BMS joins forces with insitro to develop neurodegenerative treatments
pharmaphorum
OCTOBER 29, 2020
The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression. BMS will have the option to select targets identified by insitro and then lead clinical development. Financial terms of the deal were not disclosed.
Let's personalize your content